What Levosiz-M treats: main uses and benefits

Levosiz-M is a combination medication primarily used to manage symptoms associated with allergic conditions. It combines two active agents that work through different pathways to address respiratory and skin-related allergic reactions.

Allergic Rhinitis

The medication is frequently used for the management of allergic rhinitis, which includes both seasonal allergies (hay fever) and perennial allergies (year-round sensitivities). It helps alleviate a range of nasal and ocular symptoms, such as:

• Nasal Congestion: Reducing the swelling of nasal passages to improve airflow.
• Rhinorrhea: Controlling a runny nose and excess mucus production.
• Sneezing: Decreasing the frequency of reflexive sneezing fits.
• Itching: Relieving itching in the nose, throat, or roof of the mouth.
• Watery Eyes: Reducing redness and tearing associated with environmental allergens.

Allergic Asthma and Respiratory Support

In patients who experience both asthma and allergic rhinitis, this combination helps manage the underlying inflammatory response. By addressing the narrowing of the airways and reducing mucus production, it assists in maintaining clearer respiratory function. It is often used as a long-term management strategy to prevent the onset of symptoms triggered by allergens like pollen, dust mites, or pet dander.

Chronic Urticaria and Skin Allergies

Levosiz-M is also utilized to treat symptoms of chronic idiopathic urticaria (hives). It helps in reducing:

• Skin Welts: Lowering the appearance and size of raised, red bumps on the skin.
• Pruritus: Alleviating intense itching associated with skin-based allergic reactions.

Mechanism of Action

The effectiveness of Levosiz-M stems from its dual-action approach. One component blocks histamine, a chemical responsible for immediate allergic symptoms like itching and sneezing. The second component targets leukotrienes, which are chemicals the body releases that cause inflammation, airway constriction, and mucus buildup. By addressing both pathways, the medication provides comprehensive relief from both the immediate and the inflammatory phases of an allergic response.

Official Eligibility and Contraindications for Levosiz-M

Levosiz-M (a fixed-dose combination of levocetirizine and montelukast) is subject to specific regulatory guidelines that define patient eligibility.

Contraindicated Populations (Must Not Use):

• Patients with documented hypersensitivity to levocetirizine, montelukast, or the parent compound cetirizine.
• Individuals with End-Stage Renal Disease or severe renal impairment (creatinine clearance <10 mL/min).
• Patients with rare hereditary problems, such as Lapp lactase deficiency or galactose intolerance.

Populations Requiring Special Consideration:

• Age: The tablet formulation is generally not recommended for children younger than 6 years due to inappropriate dose adaptation. Use in older adults should be cautious due to a higher frequency of reduced organ function.
• Organ Function: Patients with impaired renal function (non-severe) or hepatic impairment are eligible but require dose adjustment and close monitoring.
• Life Stages: The medicine is not recommended for use during pregnancy or lactation because safety has not been fully established, and a component may pass into breast milk.
• Clinical Status: Caution is required in patients with predisposing factors for urinary retention or those with a history of epilepsy or increased seizure risk.

Interactions with other medicines and products

This section summarizes documented drug-drug interactions for Levosiz-M, a combination of levocetirizine and montelukast, as defined in official regulatory labeling.

Documented Interaction Categories and Implications

Interaction Category	Specific Interacting Medicine Examples	Regulatory Implication/Constraint
CNS Depressants	Alcohol, Sedatives, Tranquilizers	Avoid co-administration due to enhanced risk of central nervous system (CNS) effects, such as drowsiness and impaired performance.
Drug Metabolism Inhibitors	Ritonavir, Ketoconazole, Erythromycin	Caution/Monitoring required, as these may increase plasma concentrations of the active components, increasing the risk of adverse effects.
Drug Metabolism Inducers	Rifampin, Phenobarbital	Caution/Monitoring required, as these may decrease plasma concentrations of the active components, potentially reducing effectiveness.
Monoamine Oxidase (MAO) Inhibitors	Tranylcypromine, Selegiline	Contraindicated/Avoid due to risk of serious Serotonin Syndrome.
Other Antihistamines	Diphenhydramine, Cetirizine	Avoid to prevent additive side effects and over-exposure to similar agents.

Pharmacokinetic and Pharmacodynamic Basis

Interactions primarily involve two mechanisms: pharmacokinetic alterations where strong inhibitors or inducers of CYP enzymes (specifically CYP3A4 and CYP2C8) modify the clearance of montelukast, and pharmacodynamic synergy where co-administration with other CNS depressants, including alcohol, results in additive sedative effects. Official labeling mandates restrictions ranging from complete avoidance (MAO Inhibitors, Alcohol) to requirements for careful monitoring or dose adjustment when co-administered with specific enzyme modulators (Rifampin, Ketoconazole).

How Levosiz-M Works: A Dual Mechanism of Action

Immediate Action: H1 Receptor Antagonism

Levocetirizine engages the peripheral Histamine H1 receptor as an inverse agonist . This action stabilizes the receptor in an inactive state, inhibiting the signaling cascade initiated by histamine. This molecular interference results in a decrease in microvascular permeability and modulation of sensory nerve stimulation.

---

Sustained Action: CysLT1 Receptor Blockade

Montelukast interferes with the leukotriene inflammatory pathway by acting as a competitive antagonist at the Cysteinyl Leukotriene Receptor 1 (CysLT1 receptor) . By blocking leukotrienes ( LTC4, LTD4, LTE4) from binding, the mechanism blocks a signaling cascade associated with inflammation and smooth muscle contraction. This mechanism influences the physiological state of airway diameter and affects the dynamics of mucosal tissue fluid balance.

---

Synergistic Pathway Modulation

The drug employs a dual, non-redundant mechanism that targets the acute (histamine) and sustained (leukotriene) inflammatory pathways simultaneously. This complementary action on two parallel signaling systems results in a combined influence on vascular responses and airway smooth muscle tone.

How to Use Levosiz-M: Administration Guidelines

Levosiz-M is a fixed-dose combination product containing Levocetirizine (5 mg) and Montelukast (10 mg) designed for oral administration. The medication is supplied as a film-coated tablet and is intended to be swallowed whole with liquid; the tablet should not be crushed or split.

---

Standard Dosage and Frequency

For adults and adolescents aged 15 years and older, the standard administration involves one tablet (10 mg/ 5 mg) taken once daily. To ensure consistent delivery, the dose is taken in a single intake. The medication may be taken with or without food, as its efficacy does not significantly depend on the timing of meals. The daily dose is typically taken in the evening.

---

Duration and Special Populations

Usage patterns vary based on the clinical scenario. For intermittent allergic rhinitis, such as seasonal allergies, the medication is often used until symptoms resolve and may be restarted upon recurrence. For persistent or perennial rhinitis, therapy may continue for the duration of allergen exposure.

Specific dosage modifications are necessary for certain populations. Due to the clearance pathway of the Levocetirizine component, the dosing interval is adjusted for patients with impaired renal function. The 10 mg/ 5 mg fixed-dose tablet is generally not recommended for children under 15 years, as this strength does not allow for weight-based dose adaptation.

Research Evidence / Overview of Studies for Levosiz-M

---

Evidence for Conditions Characterized by Fluctuating Symptoms

Research examined Levosiz-M in the context of Allergic Rhinitis, a condition characterized by fluctuating or episodic manifestations. The evidence base is primarily derived from short-term Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews of pooled trial data. These trials explored changes in symptoms in both adults and children aged 6 to 14.

These studies focused on measuring outcomes related to physical discomfort, primarily tracking changes in patient-reported outcomes describing perceived discomfort related to sneezing, nasal congestion, runny nose, and itching. Research reports measured changes during the study period; this evidence describes symptom patterns observed when the combination was evaluated in these populations. However, the evidence remains limited primarily to short-term observation periods, typically lasting about four weeks.

---

Evidence for Conditions Associated with Functional Limitations

Research was evaluated in patients with conditions marked by functional limitations, such as Allergic Rhinitis with co-existing Mild-to-Moderate Asthma. This evidence was derived from studies that evaluated outcomes reflecting daily functioning and specific physiological measures in primarily adult populations.

In these trials, researchers examined outcomes related to systemic or functional imbalance in the lungs. In addition to nasal symptoms, studies monitored outcomes such as pulmonary function markers, including Forced Expiratory Volume in 1 second (FEV1). It is important to note that this body of evidence is less extensive than the research for Allergic Rhinitis alone, and follow-up durations were limited for assessing long-term asthma disease management.

---

Evidence in Specific Groups and Remaining Uncertainties

Research was evaluated in certain subgroups, notably children and adults with mild-to-moderate asthma. The results apply only to the populations studied, meaning data for certain groups remain insufficient, such as for older adults or patients with severe forms of asthma. Key research limitation frames include the short-term nature of most trials and the fact that Comparative evidence is lacking for many head-to-head comparisons against other established anti-allergy medications. Long-term effects are not fully established.

Key Studies & References Montelukast (as Sodium) + Levocetirizine Hydrochloride: Product Information (Regulatory Document)

Common questions about Levosiz-M (FAQ)

---

Q: What's the difference between Levosiz-M and just plain Levocetirizine?

A: Levosiz-M is a fixed-dose combination product, meaning it contains two different active medicines in one tablet. It includes the antihistamine Levocetirizine plus a separate medicine called Montelukast, which is a leukotriene receptor antagonist. Levocetirizine alone only contains the antihistamine component. This combination is designed to target two distinct inflammatory pathways related to allergies simultaneously.

---

Q: What is the Montelukast part of Levosiz-M supposed to do?

A: Montelukast is a type of medicine known as a leukotriene receptor antagonist. According to official product information, it works by blocking chemical messengers called leukotrienes in the body. Blocking these messengers helps reduce the inflammation and swelling that contribute to symptoms in the airways and nose.

---

Q: Why does my doctor prescribe Levosiz-M for my allergy symptoms?

A: Regulatory documents indicate this combination is prescribed to relieve symptoms of both seasonal (time-limited) and perennial (year-round) allergic rhinitis, such as a runny nose, sneezing, and congestion. It is also used as part of a treatment plan for patients who have allergic symptoms that occur with co-existing mild-to-moderate asthma.

---

Q: How quickly should I expect Levosiz-M to start working for my congestion?

A: Official information regarding how the body handles the medicine (pharmacokinetics) shows that the antihistamine component, Levocetirizine, is rapidly absorbed, reaching its highest concentration about one hour after taking the tablet. The Montelukast component peaks around three to four hours. Based on the absorption timing, some relief of congestion may begin to be noticeable within a few hours.

---

Q: Is Levosiz-M mainly for seasonal allergies or year-round issues?

A: Studies and official indications confirm that the medicine is approved for the treatment of symptoms associated with both seasonal allergic rhinitis and perennial (lasting throughout the year) allergic rhinitis. Therefore, it may be used for either type of allergy, depending on the clinical scenario.

---

Q: Can Levosiz-M help with asthma symptoms as well as allergies?

A: Yes, official labeling states that the medication is commonly used as part of a treatment plan for patients who have allergic rhinitis along with co-existing mild-to-moderate asthma. The medicine is generally used for long-term control and does not replace rescue inhalers or emergency treatment.

---

Q: Does Levosiz-M cause any stomach upset or digestive issues?

A: Like many medicines, Levosiz-M may cause some gastrointestinal effects. Regulatory documents list dry mouth, nausea, and abdominal pain as commonly reported adverse reactions from clinical trials.

---

Q: Is it normal to feel drowsy after taking Levosiz-M?

A: Yes, official safety information indicates that somnolence (sleepiness) and fatigue are among the most common adverse reactions reported by patients. This is a known effect of the medicine’s antihistamine component.

---

Q: Is Levosiz-M suitable for children with allergic rhinitis?

A: The fixed-dose tablet strength of Levosiz-M (10 mg/5 mg) is generally not recommended for children under 15 years of age. This is because this specific strength does not allow for the necessary dose adjustments that are required based on a child's weight or age.

---

Q: At what age is Levosiz-M typically prescribed?

A: The standard fixed-dose tablet strength of the medication (10 mg/5 mg) is typically prescribed for adults and adolescents aged 15 years and older. Lower strength formulations may be available for younger age groups, if appropriate.

---

Q: Why might someone feel more anxious after starting Levosiz-M?

A: The official label notes that anxiety and agitation are documented adverse reactions, though they are categorized as uncommon or rare. These and other changes in thinking or behavior are listed under a specific warning concerning neuropsychiatric events associated with the Montelukast component.

---

Q: Is it better to take Levosiz-M in the morning or at night?

A: Official guidelines on the medication's use typically recommend that the daily dose be administered in the evening. Taking it at this time can help manage symptoms overnight and may reduce the impact of potential drowsiness.

---

Q: How long does the effect of one tablet of Levosiz-M usually last?

A: The formulation is prescribed for once-daily dosing, suggesting the dose is designed to cover a typical 24-hour period. This once-daily schedule is supported by the half-life data of the two components.

---

Q: What should I do if I miss a dose of Levosiz-M?

A: Patient information generally advises that a missed dose may be taken when remembered. However, it also cautions against taking two doses at once to compensate for a missed dose.

---

Q: Can Levosiz-M be stopped suddenly, or does it need to be tapered off?

A: Official information states that for intermittent allergic rhinitis (like seasonal allergies), the medicine can be stopped when symptoms have resolved. Consultation with a healthcare professional is advised before stopping any medication.

---

Q: Why do some people use Levosiz-M for chronic hives (urticaria)?

A: The Levocetirizine component of the fixed-dose combination is specifically indicated for treating the skin symptoms of chronic idiopathic urticaria, commonly known as hives. This includes reducing the itching and rash associated with the condition.

---

Q: Can Levosiz-M affect my ability to concentrate or drive?

A: Yes, the medication may cause dizziness and sleepiness (somnolence). Official warnings suggest caution for activities requiring full mental alertness, such as driving or operating machinery, if the medication causes these effects.

---

Q: Can taking Levosiz-M cause changes in mood?

A: Yes, the official label includes warnings about the potential for changes in mood or behavior. Adverse events reported include anxiety, agitation, insomnia, and irritability. These are considered uncommon to rare neuropsychiatric events.

---

Q: Why is Levosiz-M sometimes referred to as an anti-leukotriene?

A: This term refers to the Montelukast component of the combination. Montelukast is classified as a Leukotriene Receptor Antagonist (LTRA) because its primary action is to block the activity of leukotrienes, thereby targeting an allergic pathway separate from histamine.

---

Q: Is it safe to take two different allergy medicines at the same time as Levosiz-M?

A: Official labeling advises patients to avoid taking Levosiz-M with other antihistamines to prevent excessive exposure to similar agents and reduce the risk of additive side effects like drowsiness. Any decision to combine this medicine with other treatments should be made only after consulting a healthcare professional.

---

Q: Does Levosiz-M impact the immune system?

A: While the medication primarily targets inflammatory pathways, official labeling documents that, in very rare instances, systemic reactions have been reported. This includes adverse reactions like Churg-Strauss Syndrome (a form of blood vessel inflammation).

---

Q: Is it normal to have vivid dreams when taking Levosiz-M at night?

A: Official safety documents list vivid dreams and other sleep disturbances as possible, though uncommon or rare, neuropsychiatric adverse reactions. These effects are associated with the Montelukast component of the medication.

---

Q: What are the different strengths or variants of Levosiz-M?

A: The most common strength is the film-coated tablet containing 10 mg of Montelukast and 5 mg of Levocetirizine. Other formulations, such as pediatric or lower strength tablets, may be available for specific age groups.

The storage and disposal of Levosiz-M tablets must comply with official labeling to maintain product stability and ensure public safety.

Storage & Disposal Scope	Official Regulatory Requirement
Temperature Requirement	Store at a temperature below 30 C.
Environmental Protection	Must be protected from light and moisture.
Container Rules	Keep the product in the original container and ensure the container is tightly closed.
Child Protection	Must be kept out of the sight and reach of children and pets.
Disposal Protocol	Unused or expired tablets must be discarded properly and according to local regulations. Do not dispose of the medicine by flushing it down the toilet or throwing it into drains.

These instructions define how the product must be stored, protected, handled, and discarded to ensure the active ingredients remain stable until the expiration date and to prevent environmental contamination.